Jeremy Chadwick, Ph.D.

Jeremy Chadwick, Ph.D.

Chief Operating OfficeratKymera Therapeutics· In proxies 2023–2024

Pay in FY2024-31% from the year before · Kymera Therapeutics stock +58.0% the same year

Jeremy Chadwick, Ph.D. was paid $3.5M in FY2024 (Dec), down 31%. Kymera Therapeutics stock rose 58.0% that year.

Pay$100 in the stock at the end of FY22 → $161
Pay is from the Summary Compensation Table of each Kymera Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Kymera TherapeuticsPublic company · 3 yr
    • Chief Operating Officer2023 – Present · 3 yrStock in role +400%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?